SLU-PP-332 Guide

SLU-PP-332 at a glance

What it is

Synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα/β/γ); not a peptide despite common marketing

Researched for

Reported in rodent studies for endurance capacity, mitochondrial biogenesis, fatty-acid oxidation and metabolic-syndrome parameters

Commonly reported range

Community/educational protocols cite ~500 mcg–2.5 mg/day (no validated human dose exists)

Route reported

Subcutaneous injection of reconstituted vials, or oral capsules (research settings)

Reported frequency

Once or twice daily in reported protocols

Reported cycle

Community examples commonly describe 4–8 week blocks (not clinically validated)

Plasma half-life

Reported short, roughly 2–8 hours in preclinical models; not characterized in humans

Regulatory status

Not FDA-approved; investigational research chemical, research-use only; see regulatory note on anti-doping

Reported ranges from research/community — examples, not recommendations.

What it is / mechanism

SLU-PP-332 is a synthetic small molecule that acts as a pan-agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ), a family of orphan nuclear transcription factors, with reported EC50 values of roughly 98, 230 and 430 nM respectively and highest potency at ERRα. Despite the "estrogen-related" name, these receptors do not bind estrogen; they were named for structural similarity to estrogen receptors and instead regulate gene networks governing oxidative metabolism, mitochondrial biogenesis and cellular energy homeostasis. By activating these receptors, SLU-PP-332 is reported to upregulate pathways associated with aerobic exercise adaptation — hence its description as an "exercise mimetic." In published mouse work, this was linked to increased mitochondrial content, a shift toward oxidative (type IIa) muscle fibers and greater fatty-acid oxidation. It is important to note that this mechanism is characterized almost entirely in cell and rodent models, not in humans.

Researched effects

In preclinical (mouse) research, SLU-PP-332 has been reported to increase whole-body energy expenditure and fatty-acid oxidation, improve treadmill running distance and time versus vehicle controls, reduce fat-mass accumulation, and improve glucose tolerance and insulin sensitivity in metabolic-syndrome models. Researchers have also reported changes in cardiac and skeletal-muscle mitochondrial function. These are research findings in animals, not guaranteed outcomes; none of these effects have been demonstrated in controlled human trials, and human responses, effective amounts and safety are unknown.

Dosage — reported ranges (overview)

There is no established or clinically validated human dose for SLU-PP-332. Published animal studies used intraperitoneal dosing around 10–50 mg/kg (frequently 50 mg/kg twice daily for 12–28 days in mice), which does not translate directly to a human amount. Community and educational protocols circulating online commonly cite roughly 500 mcg to 2.5 mg per day by subcutaneous injection, sometimes split into two doses. These figures are examples of what is reported, not a recommendation; because no human pharmacokinetic or safety data exist, any use outside a controlled research context carries unknown risk.

The full step-by-step protocol examples, titration, and printable protocol sheet are planned for a future paid Protocol Playbook module.

Reconstitution — bac-water math

Reconstitution is concentration math only, not a personal dose. When a lyophilized vial is dissolved in bacteriostatic water, concentration is total compound divided by water volume. On a U-100 insulin syringe, 1 mL = 100 units, so units to draw = (desired dose ÷ concentration) × 100. For SLU-PP-332, note that many research vials are supplied with a small amount of a co-solvent (such as DMSO) to aid solubility — follow the vial's own directions. Worked example: a representative 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5 mg/mL (5000 mcg/mL). A 500 mcg example dose = (500 ÷ 5000) × 100 = 10 units on a U-100 syringe.

This is concentration math, not a dose recommendation.

Injection / administration basics

In reported research protocols using the injectable form, a reconstituted vial is drawn into a U-100 insulin syringe and administered subcutaneously (community reports) or intraperitoneally (rodent studies). Reported handling practices include swabbing the vial stopper and injection site with alcohol, adding bacteriostatic water slowly against the vial wall rather than directly onto the powder, gently swirling (not shaking) until dissolved, and using a fresh sterile needle each time. Subcutaneous bioavailability and pharmacokinetics in humans are not published, so these are described only as reported handling practices, not administration guidance. An oral capsule form is also sold in research settings.

Half-life & frequency rationale

SLU-PP-332 is reported to have a relatively short plasma half-life in preclinical models — roughly on the order of 2–8 hours depending on species, route and source — which is why rodent studies often used twice-daily dosing. Human pharmacokinetics, including half-life, clearance and oral bioavailability, have not been formally characterized; animal data suggest oral bioavailability is poor.

Stacking — overview

In community and educational discussion, SLU-PP-332 is most often described alongside other compounds targeting metabolism, mitochondrial function, body recomposition and recovery — reflecting its "exercise-mimetic" positioning. These pairings are examples of what is reported by users and vendors, not recommendations, and none have been studied for combined safety or efficacy in humans. The stacks below emphasize compounds also covered in our library.

Storage & handling

• Lyophilized (powder): reported to be stored cold — refrigerated at 2–8°C for near-term use or frozen (around -20°C) for longer storage — protected from light and moisture.
• Reconstituted (in solution): reported to be kept refrigerated at 2–8°C and used within a few weeks; keep away from light and avoid freeze-thaw cycles once mixed.

Guide FAQ

Quick answers about guide scope, access, and educational use context.